Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients
Authors:
- 1 November 2000
- journal article
- clinical trial
- Published by Wiley in Pediatric Transplantation
- Vol. 4 (4) , 313-321
Abstract
Cyclosporin A (CsA) is an important immunosuppressant that is prone to numerous drug interactions. Grapefruit juice has been investigated, as a possible adjunct to CsA dosing in adult renal transplant recipients, to decrease CsA metabolism and reduce dosages. This study investigated this combination in pediatric renal transplant patients. Six stable pediatric renal transplant patients were entered into an open‐label, four‐period cross‐over study in which patients were given their current CsA dose as either an oral solution (CsA‐Sol) or a microemulsion (CsA‐ME). In addition, drugs were administered concurrently with water or grapefruit juice. Steady‐state pharmacokinetic profiles were taken during each of the four periods. Following the concurrent administration of grapefruit juice, CsA whole‐blood 12‐h trough levels were significantly increased during CsA‐Sol dosing. Furthermore, the CsA elimination rate constant was significantly reduced during the same period. After CsA‐ME dosing, no differences in CsA pharmacokinetics were found between concurrent water or grapefruit ingestion. Grapefruit juice co‐administration reduced the production of CsA metabolites, AM1 and AM9, during CsA‐Sol dosing. No changes in CsA metabolite production were found when patients were given CsA‐ME with grapefruit juice as compared with water. Hence, alterations in CsA absorption and elimination occur with concurrent grapefruit juice ingestion when stable pediatric renal transplant patients are taking the oral CsA solution, but not the microemulsion formulation. These changes may be mediated by alterations in intestinal or hepatic metabolism, or drug absorption. The effect of grapefruit juice on CsA absorption is not readily predictable in these patients.Keywords
This publication has 27 references indexed in Scilit:
- Cyclosporin Pharmacokinetics in Paediatric Transplant RecipientsClinical Pharmacokinetics, 1997
- Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juiceLife Sciences, 1996
- Challenges in Cyclosporine Therapy: The Role of Therapeutic Monitoring by Area Under the Curve MonitoringTherapeutic Drug Monitoring, 1995
- REDUCED INTER- AND INTRASUBJECT VARIABILITY IN CYCLOSPORINE PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS TREATED WITH A MICROEMULSION FORMULATION IN CONJUNCTION WITH FASTING, LOW-FAT MEALS, OR HIGH-FAT MEALS1,2Transplantation, 1995
- Cyclosporin Clinical PharmacokineticsClinical Pharmacokinetics, 1993
- Pharmacokinetics of Cyclosporine in Bone Marrow Transplantation: Longitudinal Characterization of Drug in Lipoprotein FractionsJournal of Pharmaceutical Sciences, 1992
- First-pass metabolism of cyclosporin by the gutThe Lancet, 1991
- On the dose dependency of Cyclosporin a absorption and disposition in healthy volunteersJournal of Pharmacokinetics and Biopharmaceutics, 1988
- Time-Dependent Pharmacokinetics and Toxicity of cyclosporineChronobiology International, 1988
- Cyclosporine Concentration Determinations for Monitoring and Pharmacokinetic StudiesThe Journal of Clinical Pharmacology, 1986